NCT06375915View on ClinicalTrials.gov

Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

January 31, 2026

Study Completion Date

January 31, 2026

Conditions
Intrahepatic Cholangiocarcinoma
Interventions
RADIATION

radioembolization with Y-90

Radioembolization with Y-90 will be performed in nominal day 0

DRUG

Durvalumab

Following radioembolization, for 6 cycles -intravenous infusion on day 1 of each cycle

DRUG

Cisplatin

Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle

DRUG

Gemcitabine

Following radioembolization, for 6 cycles -intravenous infusion on day 1 and 8 of each cycle

Trial Locations (1)

20132

RECRUITING

Department of Radiology, IRCCS Ospedale San Raffaele, Milan

All Listed Sponsors
collaborator

Cardarelli Hospital

OTHER

collaborator

A.O. Ospedale Papa Giovanni XXIII

OTHER

collaborator

AOU Pisana, Pisa, Italy

UNKNOWN

lead

Francesco De Cobelli

OTHER